REGENXBIO Inc. SEC filings RGNX
REGENXBIO Inc. has 805 filings in SEC EDGAR's recent list, going back to Nov 7, 2013. Its latest annual report, Form ARS, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 14, 2026 | — |
| DEF 14A | Proxy statement | Apr 14, 2026 | May 29, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2026 | May 29, 2026 |
| DEFA14A | Additional proxy material | Apr 8, 2025 | — |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 30, 2025 |
| DEFA14A | Additional proxy material | Apr 4, 2024 | — |
| DEF 14A | Proxy statement | Apr 4, 2024 | May 31, 2024 |
| DEFA14A | Additional proxy material | Apr 6, 2023 | — |
| DEF 14A | Proxy statement | Apr 6, 2023 | — |
| DEFA14A | Additional proxy material | Apr 7, 2022 | — |
| DEF 14A | Proxy statement | Apr 7, 2022 | Jun 3, 2022 |
| DEFA14A | Additional proxy material | Apr 19, 2021 | — |
| DEF 14A | Proxy statement | Apr 19, 2021 | Jun 4, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 8, 2021 | Jun 4, 2021 |
| DEFA14A | Additional proxy material | Apr 8, 2020 | — |
| DEF 14A | Proxy statement | Apr 8, 2020 | May 29, 2020 |
| DEFA14A | Additional proxy material | Apr 11, 2019 | — |
| DEF 14A | Proxy statement | Apr 11, 2019 | May 31, 2019 |
| DEFA14A | Additional proxy material | Apr 12, 2018 | — |
| DEF 14A | Proxy statement | Apr 12, 2018 | May 25, 2018 |
| DEFA14A | Additional proxy material | Apr 13, 2017 | — |
| DEF 14A | Proxy statement | Apr 13, 2017 | May 24, 2017 |
| DEFA14A | Additional proxy material | Apr 18, 2016 | — |
| DEF 14A | Proxy statement | Apr 18, 2016 | Jun 1, 2016 |
Showing 24 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RGNX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1590877
- Former names
- ReGenX Biosciences, LLC (until Nov 7, 2013)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.